Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
106.28
-2.13 (-1.96%)
Feb 21, 2025, 4:00 PM EST - Market closed
Sarepta Therapeutics Stock Forecast
Stock Price Forecast
The 22 analysts with 12-month price forecasts for Sarepta Therapeutics stock have an average target of 174.64, with a low estimate of 75 and a high estimate of 230. The average target predicts an increase of 64.32% from the current stock price of 106.28.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Sarepta Therapeutics stock from 22 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 7 | 6 | 6 | 6 |
| Buy | 11 | 12 | 13 | 13 | 13 | 13 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 1 | 1 | 2 | 2 |
| Total | 18 | 20 | 22 | 21 | 22 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Sell Reiterates $75 | Strong Sell | Reiterates | $75 | -29.43% | Feb 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Sell Reiterates $75 | Strong Sell | Reiterates | $75 | -29.43% | Jan 30, 2025 |
| Needham | Needham | Strong Buy Reiterates $202 | Strong Buy | Reiterates | $202 | +90.06% | Jan 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Sell Reiterates $75 | Strong Sell | Reiterates | $75 | -29.43% | Jan 15, 2025 |
| Needham | Needham | Strong Buy Reiterates $202 | Strong Buy | Reiterates | $202 | +90.06% | Jan 14, 2025 |
Financial Forecast
Revenue This Year
1.90B
from 1.24B
Increased by 53.06%
Revenue Next Year
3.21B
from 1.90B
Increased by 68.79%
EPS This Year
2.66
from -5.80
EPS Next Year
11.52
from 2.66
Increased by 332.51%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2.0B | 3.9B | 4.6B | |||
| Avg | 1.9B | 3.2B | 4.0B | |||
| Low | 1.8B | 2.3B | 2.9B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 61.7% | 107.5% | 43.9% | |||
| Avg | 53.1% | 68.8% | 23.8% | |||
| Low | 41.6% | 19.0% | -9.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 3.45 | 18.43 | 21.99 | |||
| Avg | 2.66 | 11.52 | 16.23 | |||
| Low | 1.77 | 3.12 | 10.32 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 592.0% | 90.9% | |||
| Avg | - | 332.5% | 40.9% | |||
| Low | - | 17.0% | -10.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.